Study aims to improve understanding of sexual and pelvic floor health after female cystectomyApril 28th 2022
“We know that, in general, cystectomy in women can disrupt pelvic floor support and innervation, as well as hormonal and sexual function, but there are no good prospective data to help us fully understand pelvic floor complications following the procedure,” said Jacqueline Zillioux, MD.
Artificial Intelligence enhances treatment assessment in bladder cancerApril 22nd 2022
A computerized artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy.
Study links socioeconomic disadvantage with increased post-cystectomy mortalityApril 19th 2022
“This study really shows the power of the area deprivation index in predicting postoperative and oncologic outcomes for bladder cancer patients undergoing radical cystectomy,” said Byron H. Lee, MD, PhD, Cleveland Clinic urologist and senior author of the study.
Enfortumab Vedotin approved in EU for urothelial cancerApril 14th 2022
The approval was based on data from the phase 3 EV-301 trial, in which enfortumab vedotin reduced the risk of death by 30% versus chemotherapy in patients with heavily pretreated locally advanced or metastatic urothelial carcinoma.
Novel oncolytic immunotherapy plus pembrolizumab active in BCG-unresponsive NMIBCApril 13th 2022
Early findings from the phase 2 CORE1 trial showed that the combination of the novel oncolytic immunotherapy CG0070 and the immune checkpoint inhibitor pembrolizumab was safe and active in patients with BGG-unresponsive NMIBC.
Dr. Petrylak highlights the latest advances in metastatic urothelial cancerMarch 22nd 2022
In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.
How BCG became the standard of care for bladder cancerMarch 16th 2022
In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.
Neoadjuvant nivolumab plus gemcitabine/cisplatin found safe and efficacious in MIBCMarch 16th 2022
The BLASST-1 study presented at the 2022 ASCO Genitourinary Cancers Symposium assessed the safety and efficacy of neoadjuvant nivolumab in combination with gemcitabine/cisplatin in patients with muscle-invasive bladder cancer .
Urology Times 50 Innovations Series: BCG therapy for bladder cancerMarch 16th 2022
"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
How Botox is changing the landscape of urologic treatmentMarch 14th 2022
Min Dong, PhD, discusses the main points of the presentation he gave at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, along with the potential impact of onabotulinumtoxinA (Botox) therapies on future urologic treatment.
Impact of cisplatin ineligibility on receiving adjuvant therapy for UTUCFebruary 15th 2022
Shawn Dason, MD, discusses the findings and takeaways of the study, "How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?"